{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Off-the-Shelf Multivirus-Specific T-Cell Therapy Shows Promise in Post-HCT Setting

Activity Steps

2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

Describe the safety and efficacy of posoleucel for the treatment of viral infections in patients who have received a hematopoietic cell transplant.
Identify a production feature and target of posoleucel.

Learning Outcomes

Seventy-five percent of participants will demonstrate knowledge of the use of posoleucel to treat viral infections in patients after hematopoietic cell transplant by achieving a minimum score of 70% on the outcomes-based posttest.

Disclosures

The author, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $12.95

Credits:

ANCC 1.0 CH
DC - BON 1.0 CH
FL - BON 1.0 CH
GA - BON 1.0 CH
NM - BON 1.0 CH
SC - BON 1.0 CH
WV - BOERN 1.0 CH

Accreditation Statement

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Planner

Test Code: OT0323

Published: March 2023

Expires: 3/6/2026

Sources: Oncology Times

Required Passing Score: 4/5 (80%)

Authors: Catlin Nalley

Specialties: Advanced Practice Nursing, Oncology

Topics: Cancer , Chemotherapy